Propella Therapeutics Inc, a company that develops prescription products, has been issued with a United States patent for a new drug treatment intended for the treatment of metastatic prostate cancer, it was reported on Wednesday.
The patent includes new molecules that are designed to provide significant advantages over the present standard of care.
The patent, named Abiraterone Prodrugs, protects certain novel prodrugs that are biologically inactive compounds that the body converts into the active pharmacological agent, abiraterone. The product is a potent CYP 17 enzyme inhibitor that prevents the synthesis of testosterone and other androgens that fuel prostate cancer cells. It is dosed in a single injection that is active for 3 months, rather than the current treatment that involves daily oral dosing and fluctuating levels of a similar drug.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer